Universal Health Services
UHS
$173.25
-0.90%
Universal Health Services, Inc. Class B operates one of the largest for-profit hospital networks in the United States, delivering healthcare through 346 inpatient behavioral health centers, 29 acute care hospitals, and a broad network of outpatient and ambulatory facilities, with additional behavioral health exposure in the United Kingdom. The company is a dual-engine operator whose acute care segment generates over 55% of revenue while its higher-margin behavioral health division contributes more than 55% of pretax profits, giving UHS a differentiated margin profile versus pure-play acute care peers. The current investor narrative centers on the strategic acquisition of Talkspace, a digital behavioral health platform whose shareholder vote cleared in May 2026, positioning UHS to capture the fast-growing online therapy market even as investors weigh near-term integration costs against long-term growth optionality. At the same time, the stock has been pressured by a broader healthcare sector overhang tied to drug-pricing and tariff headlines, and by questions about payer mix, labor costs, and Medicaid supplemental payment dynamics that have kept shares range-bound despite steady operational execution.…
UHS
Universal Health Services
$173.25
Related headlines
Investment Opinion: Should I buy UHS Today?
The synthesized recommendation is Buy, with the core thesis that UHS offers a rare combination of deep value (7.28x forward PE), stable mid-single-digit revenue growth, and a higher-margin behavioral health franchise that the market is pricing for pessimism. The 17-analyst consensus rating of 'buy' with an average target price of $193.65 implies 10.8% upside, and the high target of $290.00 shows what is possible if the valuation gap closes toward historical norms.
The supporting evidence is compelling: revenue grew 9.65% YoY to $4.495 billion in Q1 2026, net income rose 10.1% to $348.7 million, and ROE stands at 20.46%. Trailing twelve-month free cash flow of $894.0 million comfortably covers capex, buybacks, and dividends, while the 13.98x interest coverage ratio provides ample debt-service cushion. The forward PE of 7.28x and EV/EBITDA of 7.01x are well below the 12-18x and 8-10x ranges typical for hospital operators, and the PEG of 0.255 implies the market is pricing in almost no growth despite consistent execution.
The biggest risks that could invalidate this thesis are Medicaid supplemental payment cuts, Talkspace integration costs exceeding expectations, and a broader healthcare sector de-rating. The rating would upgrade to a stronger Buy if forward PE remains below 8x while revenue growth accelerates above 10%, or downgrade to Hold if revenue growth decelerates below 5% or if Medicaid supplemental payments are materially reduced. On balance, UHS appears undervalued relative to both its own historical PE band and its peer group, though the discount reflects real regulatory and integration uncertainties that will take several quarters to resolve.
Sign up to view all
UHS 12-Month Price Forecast
UHS presents a compelling value opportunity with a forward PE of 7.28x that is roughly 40-60% below hospital operator peers, despite 9.65% revenue growth, 20.46% ROE, and $894 million of trailing free cash flow. The behavioral health segment's higher margins and the Talkspace acquisition provide a differentiated growth engine, while the 17-analyst consensus buy rating and $193.65 average target imply double-digit upside. The main risks are Medicaid supplemental payment uncertainty and Talkspace integration costs, both of which appear at least partially priced into the current multiple. I would upgrade to high confidence if Q2 2026 results show stable margins and successful Talkspace integration, and downgrade to neutral if revenue growth decelerates below 5% or if Medicaid supplemental payments are materially cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Universal Health Services's 12-month outlook, with a consensus price target around $193.65 and implied upside of +11.8% versus the current price.
Average Target
$193.65
0 analysts
Implied Upside
+11.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$166 - $290
Analyst target range
UHS is covered by 17 analysts with a consensus recommendation of "buy" and a recommendation mean of 2.4, indicating a moderately bullish tilt though not overwhelming conviction. The average target price of $193.65 implies approximately 10.8% upside from the current price of $174.83, a modest but positive expected return. The consensus leans constructive but cautious — the buy rating is supported by the deep valuation discount and stable operational performance, while the 2.4 mean (where 1.0 is strong buy and 3.0 is hold) suggests several analysts remain on the sidelines awaiting clearer catalysts. The estimated EPS average of $25.65 for the forward period, against a forward PE of just 7.28x, highlights the disconnect between analyst earnings expectations and the market's valuation. The target price range is wide, spanning from a low of $166.00 to a high of $290.00 — a $124 spread that signals significant disagreement about the company's trajectory. The low target of $166.00, roughly 5% below the current price, implies a bear case built on margin compression, Medicaid supplemental payment cuts, or integration challenges from the Talkspace deal weighing on profitability. The high target of $290.00, representing 65.9% upside, assumes multiple expansion toward historical norms, successful Talkspace integration opening a new digital behavioral health growth channel, and continued earnings growth that closes the valuation gap with peers. Institutional ratings show a mixed but slightly deteriorating pattern: Barclays downgraded from Overweight to Equal Weight on July 8, 2026, while TD Cowen, UBS, and Guggenheim maintained Buy ratings through mid-2026, and Wells Fargo, Baird, RBC Capital, and Cantor Fitzgerald held neutral or sector-perform stances. The wide target spread combined with the recent Barclays downgrade suggests uncertainty is elevated, and the stock's direction will likely hinge on whether upcoming quarters demonstrate that the valuation discount is unwarranted or that structural headwinds justify the market's caution.
Bulls vs Bears: UHS Investment Factors
The bull case currently has stronger evidence, anchored by a forward PE of 7.28x, a PEG of 0.255, 9.65% revenue growth, 20.46% ROE, and a consensus buy rating with 10.8% average upside. The bear case rests on genuine but largely priced-in concerns: a -42.19% max drawdown, 20.49% YTD decline, Medicaid supplemental payment uncertainty, and Talkspace integration costs. The single most important tension is whether the market's deep skepticism about reimbursement and integration risk is overdone — if Q2/Q3 2026 results show stable margins and successful Talkspace integration, the valuation gap to peers should close; if Medicaid supplemental payments are cut or integration costs spike, the discount is justified. The recent 19.40% three-month rally and 16.36-point relative strength outperformance suggest the market is beginning to resolve this tension in the bulls' favor.
Bullish
- Deep value on forward earnings: UHS trades at a forward PE of just 7.28x against estimated EPS of $25.65, a roughly 40-60% discount to the 12-18x forward earnings range typical for hospital and facility operators. The PEG ratio of 0.255 implies the market is pricing in almost no growth despite 9.65% YoY revenue growth and 10.1% net income growth.
- Behavioral health margin engine: Behavioral health contributes over 55% of pretax profits on just $1.882 billion of quarterly segment revenue versus $2.610 billion for acute care, giving UHS a structurally higher margin profile than pure-play acute care peers. The Talkspace acquisition, approved by shareholders in May 2026, extends this higher-margin franchise into the fast-growing digital therapy market.
- Strong profitability and cash generation: Q1 2026 net income of $348.7 million produced a 7.76% net margin and 20.46% ROE, while EBITDA of $661.7 million equated to a healthy 14.72% EBITDA margin. Trailing twelve-month free cash flow of $894.0 million comfortably funds $217.2 million of quarterly capex, $163.8 million of buybacks, and the dividend.
- Analyst targets imply upside: The 17-analyst consensus rating is 'buy' with an average target price of $193.65, implying roughly 10.8% upside from $174.83, and a high target of $290.00 representing 65.9% upside. The wide $166-$290 target range signals that even the bear case is only about 5% below the current price.
Bearish
- Severe long-term underperformance: Despite the recent bounce, UHS is down 8.37% over one year and 20.49% year-to-date, lagging SPY by 24.59 and 32.57 percentage points respectively. The -42.19% max drawdown shows how violently the market has repriced the stock, and the 1-year relative strength of -24.59 indicates persistent institutional selling.
- Regulatory and payer-mix overhang: The stock has been pressured by drug-pricing and tariff headlines, including the Trump administration's reported preparation of 100% tariffs on drugmakers without pricing deals. Medicaid supplemental payment dynamics and payer-mix questions remain unresolved and could compress margins if reimbursement terms tighten.
- Talkspace integration risk: The Talkspace acquisition, while strategically sound, brings near-term integration costs and execution risk into a digital business with a different cost structure than UHS's brick-and-mortar operations. Investors have explicitly been cautious about these near-term costs, and any integration misstep could weigh on 2026-2027 earnings.
- Thin liquidity and moderate leverage: The current ratio of 1.052 is tight for a capital-intensive hospital operator, and debt-to-equity of 0.757 leaves limited balance-sheet flexibility if Medicaid supplemental payments are cut. The cash flow to debt ratio of 0.078 means deleveraging would take years if the company prioritized it over buybacks and acquisitions.
UHS Technical Analysis
UHS is in a recovery phase within a broader downtrend, with the stock at $174.83 after a 1-year decline of -8.37% and a year-to-date drop of -20.49%. The current price sits at roughly 32.7% of its 52-week range of $140.08 to $246.33, meaning it is trading in the lower-middle portion of its annual band — closer to the low than the high, which suggests the market has already priced in significant pessimism rather than momentum-driven overextension. The max drawdown of -42.19% underscores how severe the prior selloff was, and the fact that shares have stabilized well above the $140.08 low implies a base may be forming rather than a continued freefall. Recent momentum has turned constructive: the stock is up 19.40% over the past three months and 1.38% over the past month, a sharp reversal from the -9.14% six-month and -8.37% one-year readings. This divergence — strong 3-month gains against negative longer-term performance — signals a potential trend reversal or at minimum a powerful mean-reversion bounce, and the relative strength figures confirm it, with UHS outperforming SPY by 16.36 percentage points over three months and 2.44 points over one month after lagging by -24.59 points over the full year. The 1-month gain of 1.38% versus SPY's -1.06% shows the stock is now attracting defensive inflows even as the broader market softens, though the modest 1-month advance relative to the 3-month surge suggests momentum is consolidating rather than accelerating. Key technical support rests at the 52-week low of $140.08, with the $142-$146 zone having been tested repeatedly in June 2026 before the July rally; resistance sits at the 52-week high of $246.33, though the more immediate ceiling is the $178-$180 area where the stock stalled in late August. A breakout above $180 on volume would confirm the recovery trend and open a path toward the $190s, while a breakdown below $140 would signal that the base has failed and expose the stock to new lows. With a beta of 1.061, UHS is only marginally more volatile than the market, meaning position sizing can be relatively standard, but the 3.77 short ratio indicates elevated short interest that could fuel a squeeze on any upside catalyst.
Beta
1.06
1.06x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$140-$246
Price range past year
Annual Return
-9.6%
Cumulative gain past year
| Period | UHS Return | S&P 500 |
|---|---|---|
| 1m | +1.9% | -2.0% |
| 3m | +17.9% | +1.4% |
| 6m | -8.6% | +15.0% |
| 1y | -9.6% | +15.7% |
| ytd | -21.2% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UHS Fundamental Analysis
UHS's revenue trajectory remains solidly positive, with Q1 2026 revenue of $4.495 billion representing 9.65% year-over-year growth over Q1 2025's $4.100 billion. The multi-quarter trend shows consistent expansion: revenue rose from $4.284 billion in Q2 2025 to $4.495 billion in Q3 2025, $4.486 billion in Q4 2025, and $4.495 billion in Q1 2026, indicating the company is sustaining roughly $4.5 billion in quarterly revenue with mid-to-high single-digit annual growth. Segment data shows acute care hospital services contributing $2.610 billion and behavioral health services $1.882 billion, with the behavioral segment's higher margins making it the more strategically valuable growth engine — a dynamic that explains the Talkspace acquisition rationale. The growth trend implies a durable investment case built on demographic demand for behavioral health services and pricing leverage in acute care, though the 9.65% YoY growth rate bears watching for deceleration in coming quarters. Profitability is robust: Q1 2026 net income was $348.7 million on a 7.76% net margin, with a gross margin of 14.64% on a cost-of-revenue basis (the 90.45% gross margin figure reflects a different accounting presentation where cost of revenue is netted differently). Operating income of $502.9 million produced an 11.19% operating margin, and EBITDA of $661.7 million equated to a 14.72% EBITDA margin — healthy for a hospital operator where 10-15% EBITDA margins are typical. The quarterly progression shows net income rising from $316.7 million in Q1 2025 to $348.7 million in Q1 2026, a 10.1% increase, while net margin improved from 7.72% to 7.76%, suggesting stable-to-expanding profitability despite wage and supply cost pressures. The balance sheet and cash flow profile is sound but not fortress-like: debt-to-equity of 0.757 is moderate for a capital-intensive hospital operator, the current ratio of 1.052 indicates tight but adequate liquidity, and ROE of 20.46% is strong, reflecting efficient use of equity capital. Free cash flow on a trailing twelve-month basis was $894.0 million, and Q1 2026 free cash flow of $184.5 million was generated after $217.2 million in capital expenditures, showing the company funds its growth internally while returning capital via $163.8 million in stock repurchases and $13.0 million in dividends. The interest coverage ratio of 13.98x provides ample cushion on debt service, and the cash flow to debt ratio of 0.078 suggests the company could deleverage over time if it chose to prioritize that over buybacks and acquisitions.
Quarterly Revenue
$4.5B
2026-03
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
14.6%
Latest Quarter
Free Cash Flow
$894018000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UHS Overvalued?
Because UHS is solidly profitable with positive net income of $348.7 million in the most recent quarter, the PE ratio is the appropriate primary valuation metric. The trailing PE of 9.31x and forward PE of 7.28x are both remarkably low in absolute terms, and the gap between them implies the market expects earnings growth — forward EPS estimates of $25.65 versus trailing earnings power suggest analysts anticipate meaningful profit expansion. A forward PE below 7.5x for a company with 20.46% ROE and 9.65% revenue growth is unusually cheap and suggests either significant market skepticism about sustainability or a genuine value opportunity. Compared to the broader healthcare sector, where hospital and facility operators often trade at 12-18x forward earnings, UHS's 7.28x forward PE represents a substantial discount of roughly 40-60%. The PS ratio of 0.798 and EV/EBITDA of 7.01x further confirm the discount — EV/EBITDA below 8x is low for a business with stable cash flows and a dominant market position in behavioral health. The PEG ratio of 0.255 is extraordinarily low, implying the market is pricing in almost no growth despite the company's consistent mid-single-digit revenue expansion and double-digit net income growth. This discount likely reflects concerns about Medicaid supplemental payment risk, regulatory uncertainty, and the integration costs of the Talkspace acquisition, but the magnitude of the discount suggests the market may be over-penalizing these risks. Historically, UHS has traded at a wide range of valuations: the PE ratio was 14.72x in Q3 2024, 8.85x in Q4 2024, 9.65x in Q1 2025, and 7.84x in Q1 2026, while the PS ratio ranged from 3.84x in Q3 2024 to 2.43x in Q1 2026. The current PE of 9.31x is near the low end of its multi-year band, and the PS ratio of 0.798 is dramatically below the 2.4-3.8x range seen in 2024-2025, though the PS discrepancy partly reflects different data timing. The PB ratio of 1.91 is also near the lower end of its historical range of 1.09x to 2.31x, suggesting the stock is priced for pessimism rather than optimism — a setup that historically has preceded mean-reversion rallies when operational results hold up.
PE
9.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~18x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on UHS's moderate leverage and tight liquidity relative to its capital intensity. Debt-to-equity of 0.757 and a current ratio of just 1.052 leave limited cushion if Medicaid supplemental payments are reduced, and the cash flow to debt ratio of 0.078 means it would take years of retained cash flow to meaningfully deleverage. The company generated $184.5 million of Q1 2026 free cash flow after $217.2 million of capex, so any revenue deceleration below the current 9.65% YoY growth rate would pressure the $163.8 million quarterly buyback and $13.0 million dividend. Revenue concentration is another risk: Nevada, Texas, and California account for 53% of 2025 operating profits, so state-level reimbursement changes in any of these markets could disproportionately hit earnings. Finally, the Talkspace acquisition introduces integration and execution risk into a digital business with a different cost structure, and near-term integration costs could compress the 11.19% operating margin.
Market and competitive risks are dominated by valuation compression and sector rotation. UHS trades at a forward PE of 7.28x, but if the market continues to apply a structural discount due to Medicaid supplemental payment uncertainty, the multiple could stay depressed or contract further even as earnings grow. The beta of 1.061 means UHS is only marginally more volatile than the market, but its 1-year relative strength of -24.59 shows it has been a persistent sector laggard, and healthcare sector rotation tied to drug-pricing and tariff headlines remains a live threat. The reported preparation of 100% tariffs on drugmakers without pricing deals creates headline risk that could spill over into hospital operators, and competitive disruption in behavioral health from digital-native platforms could pressure UHS's higher-margin segment if Talkspace does not scale effectively. The Barclays downgrade to Equal Weight on July 8, 2026, and the 2.4 recommendation mean suggest analysts see limited near-term catalysts.
The worst-case scenario would combine a Medicaid supplemental payment cut in one or more key states, a weak quarter that misses the $25.65 forward EPS estimate, and a failed Talkspace integration that forces write-downs. In that chain of events, the stock could retest its 52-week low of $140.08, which is roughly 20% below the current $174.83 price, and the analyst low target of $166.00 would likely be breached. A more severe outcome, such as a broad reimbursement overhaul, could push shares toward the lower end of the historical PE band and imply a drawdown of 25-30% from current levels, consistent with the -42.19% max drawdown already experienced. Investors should size positions knowing that a realistic adverse scenario involves a 20-25% loss to the $140 area, with tail risk extending toward $130 if multiple compression and earnings cuts occur simultaneously.
FAQ
The most severe risk is regulatory and reimbursement: Medicaid supplemental payment cuts in Nevada, Texas, or California, which account for 53% of 2025 operating profits, could materially reduce earnings. Financial risk is moderate, with debt-to-equity of 0.757 and a current ratio of 1.052 leaving limited cushion, though 13.98x interest coverage provides near-term safety. Integration risk from the Talkspace acquisition could bring unexpected costs and delay digital behavioral health profitability, pressuring the 11.19% operating margin. Competitive and macro risks include healthcare sector rotation tied to drug-pricing and tariff headlines, plus the stock's 1-year relative strength of -24.59 showing persistent underperformance versus SPY. Ranked by severity: reimbursement cuts first, integration execution second, valuation compression third, and balance-sheet constraints fourth.
The 12-month forecast has three scenarios: a 55% probability base case targeting $185-$205, aligned with the $193.65 analyst average and implying roughly 10.8% upside; a 25% probability bull case targeting $230-$290, driven by successful Talkspace integration and a PE re-rating toward 10x; and a 20% probability bear case targeting $140-$166, aligned with the 52-week low and analyst low target, if Medicaid cuts or integration issues materialize. The base case is most likely, assuming revenue growth holds at 8-10% and EBITDA margin stays above 14%. The key assumption behind the base case is that forward EPS of $25.65 is achieved without major reimbursement changes.
UHS appears undervalued on nearly every metric: the trailing PE of 9.31x and forward PE of 7.28x are near the low end of its multi-year band, versus 14.72x in Q3 2024 and 9.65x in Q1 2025. The PS ratio of 0.798 is dramatically below the 2.4-3.8x range seen in 2024-2025, and the PB of 1.91 is near the lower end of its 1.09-2.31x historical range. EV/EBITDA of 7.01x is below the 8-10x typical for hospital operators, and the PEG of 0.255 implies the market is pricing in almost no growth despite 9.65% revenue growth. The market appears to be paying a deep discount that reflects Medicaid supplemental payment risk and Talkspace integration costs, but the magnitude suggests over-penalization.
From a risk/reward perspective, UHS is attractive for value-oriented investors: the forward PE of 7.28x is roughly 40-60% below hospital peers, the consensus buy rating carries a $193.65 average target (10.8% upside), and the $290 high target implies 65.9% upside. The biggest downside risk is a retest of the $140.08 52-week low, roughly 20% below the current $174.83 price, if Medicaid supplemental payments are cut or Talkspace integration disappoints. The stock is a good buy for investors with a 12-24 month horizon who can tolerate healthcare regulatory uncertainty, but it is less suitable for those needing near-term catalysts or low volatility. Position sizing should account for the -42.19% max drawdown and the 2.4 recommendation mean, which signals only moderate analyst conviction.
UHS is better suited for medium-to-long-term investment than short-term trading. The beta of 1.061 means volatility is only marginally above the market, but the -42.19% max drawdown and 20.49% YTD decline show the stock can experience sharp drawdowns, making short-term timing difficult. The dividend yield of 0.37% is modest and the payout ratio of 3.44% is very low, so income is not the primary appeal; rather, the value proposition is multiple expansion and earnings growth over 12-24 months. Earnings visibility is reasonable given the $21.23 billion analyst revenue average and stable quarterly revenue near $4.5 billion, but the Medicaid supplemental payment overhang requires patience. A minimum suggested holding period is 12-18 months to allow the valuation discount to narrow and Talkspace integration to progress.